Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. However, its prognostic value in the rituximab immunochemotherapy era remains undefined. In...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Xu-Monette, Zijun Y., Wu, Lin, Visco, Carlo, Tai, Yu Chuan, Tzankov, Alexander, Liu, Wei-min, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Zhao, X. Frank, Choi, William W. L., Zhao, Xiaoying, van Krieken, J. Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J. M., Zhou, Fan, Kahl, Brad S., Winter, Jane N., Xu, Wei, Li, Jianyong, Go, Ronald S., Li, Yong, Piris, Miguel A., Møller, Michael B., Miranda, Roberto N., Abruzzo, Lynne V., Medeiros, L. Jeffrey, Young, Ken H.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2012
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3496956/
https://ncbi.nlm.nih.gov/pubmed/22955915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-433334
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы